Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-14.07%
+2.93%
-5.37%
+1.57%
YMAB
Y-mAbs Therapeutics
$8.52
Chart
$4.41 (+93.20%)
$4.13 (+106.30%)
$4.84 (+76.03%)
$14.31 (-40.46%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-14.07%
+2.93%
-5.37%
+1.57%
YMAB
Y-mAbs Therapeutics
Current Price
$8.52
Login to view Y-mAbs Therapeutics (YMAB) recommendation from the last 90 days from financial news and social media.
Chart
$4.41 (+93.20%)
$4.13 (+106.30%)
$4.84 (+76.03%)
$14.31 (-40.46%)
YMAB Latest Analysis
Earnings Scheduled For August 8 2025. . BeOne Medicines (NASDAQ:) is expected to report quarterly earnings at $0.01 per share on revenue of $520.00 million. . Emera (NYSE:) is likely to report quarterly earnings at $0.65 per share on revenue of $1.81 billion. . Alpha Metallurgical (NYSE:) is likely to report quarterly loss at $2.61 per share on revenue of $555.96 million. . Y-mAbs Therapeutics (NASDAQ:) is expected to report quarterly loss at $0.26 per share on revenue of $18.41 million. . Surmo
Fri Aug 8, 2025
Y-mAbs Therapeutics GAAP EPS of -$0.07 beats by $0.19 revenue of $19.53M beats by $1.13M.
Fri Aug 8, 2025
A Look Ahead: Y-mAbs Therapeuticss Earnings Forecast. Y-mAbs Therapeutics (NASDAQ:) is gearing up to announce its quarterly earnings on Friday 2025-08-08. Here'.s a quick overview of what investors should know before the release.Analysts are estimating that Y-mAbs Therapeutics will report an Y-mAbs Therapeutics s will hope to hear the company announce they'.ve not only beaten that estimate but also to provide positive guidance or forecasted growth for the next quarter.New investors shoul
Thu Aug 7, 2025
Y-mAbs soars on take-private deal with SERB Pharmaceutical.
Tue Aug 5, 2025
Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition.
Tue Aug 5, 2025
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics. Acquisition to Include DANYELZA® (Naxitamab-gqgk) Further Broadening SERBs Rare Oncology Product Portfolio
Tue Aug 5, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
YMAB Stock trends
YMAB Stock performance
YMAB Stock analysis
YMAB investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings